Literature DB >> 9255911

Heparin therapy in pediatric patients.

A H Sutor1, P Massicotte, M Leaker, M Andrew.   

Abstract

Advances in tertiary care pediatrics have resulted in heparin being one of the most frequently prescribed drugs in children's hospitals. Heparin is essential for cardiopulmonary bypass, extracorporeal membrane oxygenation, renal dialyses, maintenance of patency of venous and arterial catheters, and treatment of thromboembolic events. Currently, protocols validated in adults are used for children. However, optimal use of heparin in pediatric patients will likely differ from adults because of age-dependent physiologic and pathologic differences in hemostasis that influence the activities of heparin. The following review summarizes the influence of age on heparin anticoagulant activities, and pharmacokinetics. The indications, monitoring, therapeutic range, factors influencing dose-response relationships, and side effects of heparin therapy in pediatric patients are discussed. Finally the current and future indications for low-molecular-weight heparins in pediatric patients are summarized. Multi-centered, international clinical trials are urgently needed to assess and optimize the use of heparin in pediatric patients in a variety of clinical settings. Until these studies are completed, recommendations for adults provide guidelines for children.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9255911     DOI: 10.1055/s-2007-996103

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  8 in total

Review 1.  How We Manage Pediatric Deep Venous Thrombosis.

Authors:  Marisol Betensky; Mark A Bittles; Paul Colombani; Neil A Goldenberg
Journal:  Semin Intervent Radiol       Date:  2017-03       Impact factor: 1.513

Review 2.  Current and future management of pediatric venous thromboembolism.

Authors:  Bryce A Kerlin
Journal:  Am J Hematol       Date:  2012-02-24       Impact factor: 10.047

Review 3.  Venous thromboembolism.

Authors:  R Gera; R Kulkarni
Journal:  Indian J Pediatr       Date:  1999 Mar-Apr       Impact factor: 1.967

4.  Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients.

Authors:  W Streif; G Goebel; A K C Chan; M P Massicotte
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-09       Impact factor: 5.747

5.  Heparin-induced thrombocytopenia in the pediatric population: a review of current literature.

Authors:  Niyati H Vakil; Abir O Kanaan; Jennifer L Donovan
Journal:  J Pediatr Pharmacol Ther       Date:  2012-01

6.  Coagulations Studies Do Not Correlate With Each Other or With Hematologic Complications During Pediatric Extracorporeal Membrane Oxygenation.

Authors:  Shyam J Deshpande; Sally Vitali; Ravi Thiagarajan; Steven Brediger; Michael McManus; Alon Geva
Journal:  Pediatr Crit Care Med       Date:  2021-06-01       Impact factor: 3.971

Review 7.  Anticoagulant therapy in pediatrics.

Authors:  Mariam K Dabbous; Fouad R Sakr; Diana N Malaeb
Journal:  J Basic Clin Pharm       Date:  2014-03

8.  Procoagulant in vitro effects of clinical cellular therapeutics in a severely injured trauma population.

Authors:  Mitchell J George; Karthik Prabhakara; Naama E Toledano-Furman; Brijesh S Gill; Charles E Wade; Bryan A Cotton; Andrew P Cap; Scott D Olson; Charles S Cox
Journal:  Stem Cells Transl Med       Date:  2020-01-06       Impact factor: 6.940

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.